nalbuphine + esketamine

Nalbuphine + esketamine is a combination of two pharmaceutical agents used primarily for pain management and perioperative analgesia. Nalbuphine is a synthetic opioid analgesic with mixed agonist-antagonist activity, acting as an agonist at kappa opioid receptors and an antagonist at mu opioid receptors, providing potent analgesia with a ceiling effect on respiratory depression[2][6]. Esketamine is the S-enantiomer of ketamine and acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, producing dissociative anesthesia, analgesia, and antidepressant effects[1][8]. The combination has been studied for optimizing post-operative pain control (e.g., after cesarean section), leveraging nalbuphine’s opioid-sparing properties alongside esketamine’s rapid-acting NMDA antagonism to enhance analgesic efficacy while potentially reducing adverse cardiorespiratory events compared to traditional regimens[4]. Both drugs are administered parenterally in this context.